Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
Early initiation of TNF inhibitors among children with non-sJIA led to significant and sustained improvements in disease activity.
Researchers found that early initiation of tumor necrosis factor (TNF) inhibitor therapy among children diagnosed with nonsystemic juvenile idiopathic arthritis (non-sJIA) at 2 years or less leads to significant and sustained improvements in disease activity.
Study results, presented at the American College of Rheumatology (ACR) Convergence 2025, used data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from 2015 to 2023.
Authors aimed to describe demographic and disease characteristics of children! diagnosed with non-sJIA from 0 to 23 months.
No direct quotes available in the text.
Summary: Early TNF inhibitors improve non-sJIA outcomes.
More News
- Kate Hudson and Son Ryder Coordinate in Paris
- Ryder — Founder and Leader of the PAW Patrol Team
- Big Bash League upcoming match schedule
- The 400 million reasons behind Cricket Australia’s Big Bash sale
- [Transaction majeure pour un top-6 : c'est confirmé pour trois nom chez le Canadien]
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- DansLesCoulisses.com | Pour en savoir plus que les autres!
- Babar Azam, Mohammad Rizwan in focus: PCB clears Big Bash NOCs for Pakistan players
- Tom & Luke Low Carb Snackaballs recall
- Katy Perry en couple avec Justine Trudeau : l’ex-Premier ministre la regarde